Atlantic American Corporation has received a significant update regarding its trading status on the Nasdaq Global Market. On November 11, 2026, the company was notified by the Nasdaq Hearings Panel that it has granted the company's request to extend the stay of the trading suspension of its common stock. This decision allows Atlantic American to appeal a previous determination from the Nasdaq Listing Qualifications Department that aimed to delist the company's shares.
This matter is crucial not only for Atlantic American but also for the broader life insurance industry, which is currently navigating various regulatory challenges. The company is scheduled for a hearing on December 1, 2026, where it will present its case to the Panel.
Background
Atlantic American Corporation, incorporated in Georgia, is primarily engaged in the life insurance sector, classified under SIC 6311. The company trades on the Nasdaq under the ticker symbol AAME. Recent filings indicate that the company has faced challenges in meeting its reporting obligations, which led to the recent delisting determination.
What the Filing Says
The recent SEC filing states, "the Panel has granted the Company’s request to extend the stay of the trading suspension of the Company’s common stock from the Nasdaq Global Market pending the outcome of the Company’s hearing before the Panel scheduled for December 1, 2026." This indicates a temporary reprieve for Atlantic American as it prepares for the upcoming hearing.
Impact
This development may affect various stakeholders, including shareholders and potential investors, who are watching closely to see if Atlantic American can successfully appeal the delisting decision. The outcome of the hearing could also impact the company’s operations and market perception.
What's Next
The next significant event will be the hearing scheduled for December 1, 2026, where Atlantic American will present its case to the Nasdaq Hearings Panel. The filing does not specify what happens next beyond this hearing.
Read Next
OZ Vision Inc. issues amended report on financial statements
Lucidi Bruno Reports Stock Transactions in Atea Pharmaceuticals
Atea Pharmaceuticals director sells 8,750 shares of stock
Grove Collaborative director Jason Karp increases stock holdings
Nason Jennifer Reports Grant of Restricted Stock Units
Suncrete, Inc. Director Andrew Heyer Acquires 25,000 Shares





